Skip to content
OpenCapital
Get started

Organogenesis Holdings Inc. ORGO Cash & Equivalents

Cash & Equivalents at other companies

IAR
Integra LifeSciencesIART
$236.81M-1.0%
MiMedx Group logo
MiMedx GroupMDXG
$159.77M+50.1%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$120.28M+108%
Bioventus logo
BioventusBVS
$35.85M+57.2%
Artivion logo
ArtivionAORT
$55.76M+47.9%
Axogen logo
AxogenAXGN
$84.65M+251%

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
Enterprise value$260.72M-21.3%
P/E115×—
P/S0.6×-0.3×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin0.5%—
Net margin0.5%+0.3pp
FCF margin6.9%—

Returns & leverage

See full
Return on equity1.1%+0.6pp
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s cash & equivalents?
Organogenesis Holdings Inc. (ORGO) reported cash & equivalents of $91.38M in Q1 2026.
How has Organogenesis Holdings Inc.'s cash & equivalents changed year-over-year?
Organogenesis Holdings Inc.'s cash & equivalents decreased by 16.9% year-over-year, from $109.97M to $91.38M.
What is the long-term trend for Organogenesis Holdings Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Organogenesis Holdings Inc.'s cash & equivalents has grown at a 2.1% compound annual growth rate (CAGR), from $84.39M to $93.68M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.